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The ANKRD1/CARP gene encodes a muscle-speciﬁc protein which has been implicated in transcrip-
tional regulation and myoﬁbrillar assembly. Several features at both the mRNA and protein levels
deﬁne ANKRD1 as a gene whose expression is tightly regulated, and deregulated expression of this
protein has been recently associated to human congenital heart disease. It is therefore crucial to
deﬁne the intracellular pathways that regulate the ANKRD1 protein’s steady-state levels. Here, we
show that ANKRD1 is a short-lived protein whose levels are tightly regulated by the 26S proteasome.
In addition, a critical role for a putative PEST motif was established, although other degrons within
the ANKRD1 protein are likely implicated in the control of its intracellular levels.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Intracellular proteolysis has long been recognized as a wide-
spread mechanism for the regulation of gene function at the pro-
tein level [1,2]. Indeed, eucaryotic cells are endowed with
sophisticated regulatory mechanisms controlling the turnover rate
of a host of proteins, including cyclins and cell cycle-related pro-
teins, structural proteins, cell-surface receptors and transcription
factors [3–5]. These observations led to the well established con-
cept that regulated proteolysis plays an essential role in a wide
range of biological processes such as cell proliferation, differentia-
tion, apoptosis and development.
Although many distinct intracellular proteases (such as the cal-
pain family members and the lysosome-associated acid proteases)
are involved in the regulation of protein intracellular levels [6,7], a
major role for the control of protein turnover rates has been as-
signed to the 26S proteasome. Indeed, this evolutionarily wide-
spread protein degradation machinery is involved in the
regulation of the intracellular levels for a wide range of proteinschemical Societies. Published by E
. Acquati).
bryology, Academic Medical
, The Netherlands.which have been related to all the above-mentioned biological pro-
cesses [8].
As far as the involvement of controlled proteolysis in develop-
mental processes is concerned, among the candidate proteins
underlying such regulatory mechanisms are those involved in the
regulation of gene expression. Indeed, several reports have demon-
strated in recent years the role of the 26S proteasome in control-
ling the intracellular stability of a host of transcription factors [9].
Recently, we reported experimental evidences pointing at
ANKRD1/CARP, which encodes a cardiac-speciﬁc transcriptional
repressor, as a candidate gene for Total Anomalous Pulmonary Ve-
nous Return (TAPVR), a cardiac developmental anomaly accounting
for 1.5% of all human congenital heart diseases [10]. A preliminary
characterization of TAPVR-associated mutations led us to envision
the tight regulation of intracellular ANKRD1 levels as a critical fac-
tor for the execution of heart developmental processes underlying
the proper connection of the pulmonary veins to the atrial cham-
bers [11]. Therefore, investigation of the intracellular pathways in-
volved in the regulation of ANKRD1 protein levels might contribute
to a better deﬁnition of the molecular mechanisms underlying its
function in the developing heart.
Here, we provide experimental evidence showing that TAPVR-
associated mutations indeed affect the in vivo intracellular stabil-
ity of this protein, thus suggesting that regulation of ANKRD1 lev-
els represents a critical mechanism for this protein’s function.lsevier B.V. All rights reserved.
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above-mentioned process.
2. Materials and methods
2.1. Chemicals
Cycloheximide and NH4Cl were purchased from Sigma and
Merck, respectively. MG-132 and calpeptin (from Calbiochem)
were dissolved in DMSO.
2.2. Plasmid constructs
Wild-type ANKRD1 cDNA was tagged with a triple FLAG epitope
(3FLAG) by PCR-ampliﬁcation and cloning into pcDNA3 expression
vector (Invitrogen). Triple-FLAG T116 M and D-PEST variants were
generated by overlap extension PCR. The 1-107 and D(5–125)
ANKRD1 deletion mutants were assembled by PCR-ampliﬁcation
from wild-type ANKRD1 cDNA and cloning into the same pcDNA3
vector. Untagged or FLAG-tagged wild-type, T116 M, and D-PEST
ANKRD1 coding sequences were also cloned in pIRESneo3 (Clon-
tech) for stable transfection in HeLa and SK-MES-1 cells. The
GFP-PEST construct was assembled by cloning a short cDNA frag-
ment encoding ANKRD1’s PEST motif (aa 107–125) in frame with
the EGFP coding region from the pEGFP-C3 vector (Clontech).
pMT123, a vector expressing inﬂuenza virus hemagglutinin HA-
tagged ubiquitin, and the empty HA-tagged expression vector were
kindly provided by Dr. D. Bohmann (University of Rochester Med-
ical Center). The sequences of all primers used in cloning strategies
are available upon request. The pEGFP-N1 plasmid (Clontech) was
used to normalize transfection efﬁciencies.
2.3. Cell culture and transfections
HeLa cells were cultured in DMEM/F12 (Sigma) supplemented
with 10% Fetal Bovine Serum (FBS) and 2 mM glutamine. The SK-
MES-1 cell line was maintained in DMEM (Sigma) supplemented
with 10% FBS and 2 mM glutamine. For stable transfections, 2 lg
of recombinant constructs in pIRESneo3 were transfected in HeLa
or SK-MES-1 cell lines using Lipofectamine 2000 Reagent (Invitro-
gen). HeLa and SK-MES-1 clones were selected in 400 or 800 lg/mL
G-418 (Gibco), respectively, and expression levels were assayed by
immunoblot analysis with M2 anti-FLAG monoclonal antibody
(Sigma). HeLa cells were also transiently transfected with pEGFP-
N1 vector, pEGFP-C3-PEST and pcDNA/ANKRD1-3FLAG deletion
mutants expression vectors at a 1:1.5 ratio, using Lipofectamine
2000 Reagent; salmon sperm DNA was used to keep the total
amount of transfected DNA constant at 4.25 lg. For ubiquitin
incorporation assays, HeLa cells were transfected with a standard
calcium phosphate transfection method.
2.4. Immunoblotting
Cells were harvested by scraping and sonicated in 50 mM Tris-
HCl, pH 8, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Nonidet P-
40 and 1 mM PMSF, 1 lg/mL aprotinin, 1 lg/mL leupeptin and
1 mM benzamidine. Following incubation at 4 C for 15 min and
centrifugation at 12 000g for 15 min at 4 C, supernatants were
collected and stored at 20 C. Protein concentration was deter-
mined with the Bradford protein assay (Bio-Rad). Cell lysates
(40 lg) were resolved by SDS–PAGE and transferred to PVDF mem-
branes (Millipore). 3FLAG-tagged ANKRD1 variants were detected
with the anti-FLAG antibody at a concentration of 2.5 lg/mL. Load-
ing controls were performed by detecting a-tubulin with anti-a-
tubulin DM 1A (Sigma) at a dilution of 1:1000. GFP and HA-taggedubiquitin were detected with monoclonal anti-GFP and anti-HA
(clone 12CA5) antibodies (Roche) diluted at 1:3000 and 1:2000,
respectively. Membranes were then incubated with secondary goat
anti-mouse antibody conjugated to horseradish peroxidase (HRP)
(Pierce) diluted at 1:900. For the detection of endogenous ANKRD1
protein, 80 lg of total cell extracts were subjected to SDS–PAGE
and electroblotted onto a PVDF membrane. Protein levels were de-
tected with polyclonal anti-CARP (H-120) antibody (Santa Cruz
Biotechnology Inc.) at 1:500 dilution. After washing, the mem-
brane was incubated with secondary goat anti-rabbit antibody
conjugated with horseradish peroxidase (Pierce), diluted at
1:900. Antibody complexes were visualized with SuperSignal West
Dura Extended Duration Substrate or SuperSignal West Femto
Maximum Sensitivity Substrate (Pierce).
2.5. ANKRD1 half-life determination
Stably transfected or untransfected SK-MES-1 and stably trans-
fected HeLa cells were plated 24 h prior to treatment with 100 lg/
mL cycloheximide. Cells harvesting and immunoblot analysis at
the appropriate time points were carried out as described above.
Untagged or FLAG-tagged ANKRD1 variants or endogenous
ANKRD1 levels were determined by densitometric analysis using
ImageJ (rsb.info.nih.gov/ij), following normalization with a-tubu-
lin levels. The rate of protein decay was determined as described
in [12] from four to ﬁve independent experiments.
2.6. Immunoﬂuorescence
HeLa cells transfected with ANKRD1-3FLAG variants were cul-
tured on coverslips, ﬁxed with 3% paraformaldehyde at room tem-
perature and permeabilized with 0.5% Triton X-100 for 10 min on
ice. After blocking with 2% BSA for 60 min at 37 C, samples were
incubated with monoclonal M2 anti-FLAG antibody diluted at
1:50, for 1 h at room temperature. Coverslips were then incubated
with FITC AfﬁniPure Fab Fragment Donkey Anti-Mouse IgG (H + L)
(Jackson ImmunoResearch Lab Inc.) diluted at 1:150 for 1 h at room
temperature. Filamentous actin was stained with Phalloidin-
tetramethylrhodamine B isothiocyanate conjugate (Fluka) at the
dilution of 1:150. Images were captured using an Olympus IX51 in-
verted microscope equipped with a Nikon DXM1200F digital cam-
era and analyzed with Confocal Assistant 4.02 (Cas40) software.
2.7. Ubiquitin incorporation assay
Untransfected or wild-type ANKRD1-3FLAG-expressing HeLa
cells were transfected with 15 lg of HA-ubiquitin, HA-K48R-ubiq-
uitin mutant or an empty HA expression vector. Cells were grown
for 24 h and DMSO or 20 lM MG-132 was added before culture
was continued for 3 h. Cell extracts were prepared as described
above and equal protein amounts were immunoprecipitated with
EZview Red ANTI-FLAG M2 Afﬁnity Gel (Sigma) according to the
manufacturer’s protocol. Levels of ubiquitinated proteins and
ANKRD1-3FLAG in cell extracts were monitored by immunoblot
with anti-HA antibody or anti-FLAG antibody.
3. Results and discussion
3.1. ANKRD1 is a short-lived protein whose intracellular stability is
controlled by the PEST motif
We previously reported two independent TAPVR-associated
mutations resulting in a signiﬁcant increase in the expression lev-
els of ANKRD1 at either the transcript or protein levels [11]. In par-
ticular, a T116 M missense mutation within a putative PEST motif
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stability and transcriptional repression activity of the ANKRD1 pro-
tein [11]. Therefore, we postulated the occurrence of a mechanism
for intracellular regulation of ANKRD1 levels by means of PEST-
mediated protein degradation.
To investigate this issue, three expression constructs encoding
wild-type, T116 M or a PEST-deleted FLAG-tagged ANKRD1 protein
were assembled as described in materials and methods and used to
investigate the intracellular pathways controlling its turnover rate.
To verify that the overall structure of the proteins encoded by these
expression constructs was not affected, we evaluated their intra-
cellular localization by immunoﬂuorescence assays following
transfection of the above-mentioned constructs into HeLa cells.
As shown in Fig. 1, both the intracellular localization and signal
intensity were quite similar for all three protein variants, suggest-
ing that ANKRD1 overall structure was not signiﬁcantly affected by
the T116 M and D-PEST mutations. Indeed, all three protein vari-
ants were localized in the nucleus, as previously described for a
functional ANKRD1 protein [13]. Moreover, a functional study car-
ried out by transient co-transfection assays in HeLa cells with a
cardiac ANF promoter-driven luciferase-encoding recombinant
construct showed that the ANKRD1 T116 M variant was function-
ally competent as a heart-speciﬁc transcriptional repressor (Sup-
plementary Fig. 1). Actually, this mutant ANKRD1 protein proved
to be even a slightly more effective transcriptional repressor when
compared with the wild-type protein, in keeping with our previous
in vitro data showing an increased intracellular stability of
ANKRD1 upon replacement of threonine 116 with methionine [11].
We then turned our attention to the stability of wild-type and
mutant ANKRD1 proteins in vivo. To this aim, the half-lives of
wild-type, T116 M and D-PEST FLAG-tagged ANKRD1 proteinsFig. 1. Immunolocalization of ANKRD1 protein variants. HeLa cells stably transfected with
indirect immunoﬂuorescence using an anti-FLAG antibody followed by ﬂuorescein isot
stained with rhodamine-phalloidin (middle column). Merged images reveal that all ANKwere compared in stably transfected HeLa cells following treat-
ment with the protein synthesis inhibitor cycloheximide (CHX).
In these experiments, the level of wild-type ANKRD1 protein de-
creased rapidly upon CHX treatment, with a half-life of
36 ± 5 min (means ± S.E.), showing that ANKRD1 is a short-lived
protein (Fig. 2). This ﬁnding is in agreement with previous reports
suggesting a tight regulation for ANKRD1 expression at both the
RNA and protein levels [13].
Moreover, consistent with our previous in vitro studies, the
T116 M mutation was found to signiﬁcantly increase the stability
of ANKRD1 in vivo, showing a half-life of 57 ± 8 min (means ± S.E.)
(Fig. 2). Thus, replacement of threonine 116 with a ‘‘non-PEST”
methionine residue apparently confers an increased in vivo stabil-
ity to the protein, conﬁrming the relevance of the PEST motif for
ANKRD1 intracellular turnover. This conclusion was further
strengthened by the observation that deletion of the whole PEST
motif further increased ANKRD1 stability in vivo, with a half-life
of 67 ± 9 min (means ± S.E.) (Fig. 2). The homogeneity of the b val-
ues (slopes) for the regression lines shown in Fig. 2 was assessed by
performing a test of parallelism. By this analysis, the differences in
slopes between wild-type ANKRD1 and either T116 M or DPEST
variants were statistically signiﬁcant (with P-values 4.07  109
and 3.1  105, respectively), whereas the difference between
T116 M and DPEST ANKRD1 did not reach statistical signiﬁcance
(P-value: 0.58).
Since these experiments were performed with exogenous,
FLAG-tagged proteins, we determined whether endogenous
ANKRD1 is also a short-lived protein. Due to undetectable ANKRD1
protein levels in HeLa cells, we turned our attention to the lung
epithelium-derived SK-MES-1 cell line, whose ANKRD1 protein
levels were previously shown to be detectable by western blotwild-type, T116 M orD-PEST ANKRD1-3FLAG expression vectors were subjected to
hiocyanate-conjugated anti-mouse antibody (left column). Filamentous actin was
RD1 variants localize into the nucleus (right column). Magniﬁcation 200.
Fig. 2. Determination of ANKRD1 variant’s half-life. (A) The half-life of recombinant ANKRD1-3FLAG protein variants was determined in stably transfected HeLa cells
following CHX treatment at the indicated times. ANKRD1 protein levels were detected by immunoblotting with anti-FLAG antibody, whereas protein loading was monitored
with anti-a-tubulin. (B) The rate of decay was determined by linear regression analysis as described in [12]. Signiﬁcance of the b value (slope) for each regression line was
tested by ANOVA: the corresponding P-values were 3.08  108 for wild-type CARP, 1.52  106 for T116 M CARP and 7.28  1012 for DPEST CARP, respectively. Values are
indicated as means ± S.E.
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turnover rate also for endogenous ANKRD1, with a half-life of
approximately 18 ± 1 min. (means ± S.E.) in this cell line (Supple-
mentary Fig. 2). Moreover, when half-lives were compared for
ANKRD1 proteins which were matched for the presence or absence
of the FLAG-tag, most of the variability between SK-MES-1 and
HeLa cell lines actually disappeared. Indeed, when untagged
ANKRD1 proteins were analyzed in HeLa and SK-MES-1, they
turned out to be degraded quite rapidly with a similar half-life in
both cell lines, in keeping with our hypothesis of ANKRD1 being
a short-lived protein (Supplementary Figs. 2 and 3).
3.2. ANKRD1 is ubiquitylated and processed by the 26S proteasome
We then turned our attention to the intracellular pathway(s)
responsible for the rapid ANKRD1 turnover. The contribution of
the lysosome/endosome, calpain and 26S proteasome pathways
was therefore assessed by transfection of HeLa cells with FLAG-
tagged wild-type ANKRD1, followed by incubation of the cells with
CHX in the presence or absence of speciﬁc inhibitors of the afore-
mentioned proteolytic pathways. As shown in Fig. 3A, the decrease
in ANKRD1 protein levels observed 180 minutes after CHX treat-
ment was not affected by NH4Cl, thus ruling out involvement of
the lysosomal degradation pathway in the intracellular ANKRD1
turnover. The same conclusion was drawn from the experiments
performed with the calpain pathway’s inhibitor calpeptin (Fig. 3A).
However, when the same assay was carried out with the 26S
proteasome inhibitor MG-132, a signiﬁcant stabilization of the
wild-type ANKRD1 protein was observed either in the presence
or absence of CHX (Fig. 3A, right). Indeed, MG-132 treatment al-
most completely prevented the CHX-mediated decay of ANKRD1
levels, suggesting that intracellular turnover of wild-type ANKRD1
is mainly carried out by the 26S proteasome. To further verify this
hypothesis, we asked whether ANKRD1 might serve as a substratefor ubiquitylation. To this end, FLAG-tagged wild-type ANKRD1-
expressing HeLa cells were transiently transfected with a HA-
tagged ubiquitin expression vector and immunoprecipitation as-
says were carried out as described in material and methods. As
shown in Fig. 3B, western blot analysis of the immunoprecipitated
proteins showed that, whereas no ubiquitinated protein bands
could be detected in the absence of MG-132, preincubation of
the cells with this proteasomal inhibitor clearly led to the accumu-
lation of ANKRD1-ubiquitin conjugates. Therefore, ANKRD1 is tar-
geted to the 26S proteasome for degradation by means of the
classical ubiquitylation pathway. Moreover, the extent of ANKRD1
ubiquitination was decreased when a HA-tagged K48R mutant re-
placed wild-type ubiquitin in the immunoprecipitation assay (Sup-
plementary Fig. 4). This result suggested a direct role for lysine
residue 48 in ANKRD1 ubiquitination. However, residual ANKRD1
ubiquitination was observed in the presence of the K48R mutant
form of HA-tagged ubiquitin, suggesting that other lysine residues
besides K48 might represent additional targets for ubiquitination.
Since the data described above were obtained with exogenously
expressed ANKRD1 protein, in order to conﬁrm that endogenous
ANKRD1 also undergo 26S proteasome-mediated processing we
investigated its intracellular degradation pattern in the above-de-
scribed SK-MES-1 cell line. As shown in Fig. 4, endogenous ANKRD1
was also clearly susceptible to 26S proteasomal degradation, since
its intracellular levels were signiﬁcantly increased by MG-132,
either in the presence or absence of CHX. Therefore, either endog-
enous or exogenous ANKRD1 is degraded by the 26S proteasome.
3.3. Several degrons independently target ANKRD1 to the 26S
proteasome
Our previous results suggested that the PEST motif might repre-
sent a destabilization domain for ANKRD1. We thus decided to
investigate its role in proteasomal-mediated degradation. To this
Fig. 3. The ubiquitin–proteasome system is involved in ANKRD1 degradation. (A) HeLa cells expressing wild-type ANKRD1-3FLAG were treated with 20 lM NH4Cl, calpeptin
or 20 lM MG-132 along with 100 lg/mL CHX for 180 min. ANKRD1 protein levels were determined by immunoblotting with anti-FLAG antibody; protein loading was
monitored by immunoblotting with anti-a-tubulin. (B) The ubiquitin incorporation assay shows that ANKRD1 is ubiquitinated in vivo, since polyubiquitinated ANKRD1
accumulates in the presence of MG-132 (lane 4).
Fig. 4. Endogenous ANKRD1 is degraded by the 26S proteasome. (A) SK-MES-1 cells expressing endogenous ANKRD1 were treated with MG-132 and CHX for 90 min as
described in Fig. 3. Cell extracts were then subjected to immunoblotting analysis with anti-CARP (H-120) and anti-a-tubulin antibodies. (B) The bar graph on the right side
shows the relative endogenous ANKRD1 levels, normalized by using the a-tubulin signal as an internal reference.
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and D-PEST FLAG-tagged ANKRD1 were incubated for 180 min
with CHX in the presence or absence of MG-132 and protein levels
were detected by immunoblot analysis. As shown in Fig. 5A, treat-
ment of the cells with CHX alone led to a decrease in the protein
levels for either wild-type or PEST-mutated ANKRD1. Thus,
although mutations or deletion of the PEST motif can provide some
stabilization upon ANKRD1, the protein can still be degraded in the
cell. Moreover, treatment with MG-132 alone led to a signiﬁcant
increase of ANKRD1 levels not only for the wild-type but also for
the two protein variants tested, suggesting that ANKRD1 can be
targeted to the 26S proteasome even in the absence of a functional
PEST motif (Fig. 5A). These results suggest the occurrence of otherdegrons besides the PEST motif which can target ANKRD1 to the
26S proteasomal pathway.
When CHX and MG-132 treatments were combined, the protein
levels of wild-type and T116 M ANKRD1 variants almost com-
pletely returned to those observed in untreated cells (Fig. 5A),
again suggesting the crucial role of the 26S proteasome in
ANKRD1’s intracellular turnover. Noteworthy, MG-132 could only
partially restore the protein levels of D-PEST ANKRD1 to those ob-
served in untreated cells (Fig. 5A). This result suggests that
ANKRD1 is at least in part targeted to the 26S proteasome through
the PEST motif, although a different pathway for ANKRD1 degrada-
tion might also be called into action following removal of the PEST
motif.
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ANKRD1 degradation by the 26S proteasome, we investigated its
ability to affect the intracellular stability of a heterologous stable
protein. As shown in Fig. 5B, the intracellular stability of the Green
Fluorescent Protein (GFP) protein was signiﬁcantly reduced follow-
ing the addition at its C-terminus of an isolated ANKRD1’s PEST
motif. Such an effect was clearly dependent on the 26S protea-
some, since the speciﬁc inhibitor MG-132 could easily restore
CHX pre-treatment expression levels of the GFP-PEST protein. This
experiment provided a very strong support for a role of the PEST
motif in the control of ANKRD1 turnover.Fig. 5. The PEST motif is involved in the proteasomal degradation of ANKRD1, but other
variants were treated with 20 lM MG-132 along with 100 lg/mL CHX for 180 min. Ce
tubulin antibodies. The bar graph (right side) shows the relative levels of the differen
transiently transfected with the pEGFP-C3-PEST or the pEGFP-N1 expression vectors and
were subjected to immunoblotting analysis with both anti-GFP and anti-a-tubulin an
normalized with a-tubulin.
Fig. 6. Multiple degrons exist in ANKRD1. HeLa cells transiently transfected with ANKR
along with 100 lg/mL CHX for 180 min. ANKRD1 protein levels were determined by imm
anti-a-tubulin and transfection efﬁciency was monitored by immunoblotting with anti-
deletion mutant to avoid inconsistent results due to the N-end rule.Thus, the short half-life of ANKRD1 in vivo is attributable to a
large extent to the 26S proteasome, and mutations or removal of
the PEST motif might signiﬁcantly affect both the nature of the
underlying degradative pathways acting upon ANKRD1 and the ex-
tent to which they effectively process the protein inside the cells,
changing its half-life accordingly.
Our data also suggest that targeting of ANKRD1 to the 26S pro-
teasome is not entirely dependent on the PEST motif, since prote-
asomal degradation could be observed in the presence of either a
‘‘weak” PEST-bearing or a completely PEST-null protein. Thus,degrons occur besides this motif. (A) HeLa cells expressing ANKRD1-3FLAG protein
ll extracts were subjected to immunoblotting analysis with anti-FLAG and anti-a-
t ANKRD1-3FLAG variants, normalized to those of a-tubulin. (B) HeLa cells were
treated with MG132 and CHX as indicated in material and methods. Cell extracts
tibodies. The bar graph on the right shows the relative GFP or GFP-PEST levels,
D1-3FLAG deletion mutants expression vectors were treated with 20 lM MG-132
unoblotting with anti-FLAG antibody, whereas protein loading was detected with
GFP. The ﬁrst four N-terminal residues of ANKRD1 were included in the D(5–125)
2492 I. Badi et al. / FEBS Letters 583 (2009) 2486–2492ANKRD1 could be targeted to the 26S proteasome through multiple
independent degrons.
In a preliminary attempt to deﬁne other regions involved in
proteasomal degradation, two truncated ANKRD1 proteins, span-
ning either the N-terminal or C-terminal moieties with respect to
the PEST motif, were expressed in HeLa cells to evaluate their sen-
sitivity to 26S proteasome-mediated degradation. As shown in
Fig. 6, both truncated proteins were rapidly degraded in the pres-
ence of CHX, whereas the proteasomal inhibitor MG-132 protected
both proteins from degradation, clearly suggesting that multiple
domains can independently target ANKRD1 for 26S proteasome-
mediated degradation.
In conclusion, we have demonstrated that the cardiac transcrip-
tional repressor ANKRD1 is a short-lived protein whose intracellu-
lar levels are regulated by processing through the 26S proteasome.
Despite several features of the ANKRD1 gene, such as the presence
of mRNA decay elements in the 30-UTR region and the occurrence
of a PEST motif within the encoded protein [13,14], have long sug-
gested that ANKRD1 undergoes a tight intracellular regulation, this
is to our knowledge the ﬁrst report deﬁning the role of a particular
degradation pathway in ANKRD1 turnover. Moreover, we have
shown that the putative PEST motif of ANKRD1 is indeed involved
in controlling its stability, although we also obtained preliminary
evidence suggesting that other regions besides the PEST motif are
also involved in the regulation of the intracellular levels of this pro-
tein. Further investigations are surely warranted to better address
this issue.
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